An Introduction to Immunotherapy
Cancer immunotherapy has brought significant improvements for patients in terms of survival and quality of life. Monoclonal antibodies and immune checkpoint inhibitors are now an established part of the treatment paradigm for many types of cancer, but challenges remain around its efficacy, targeting and toxicity.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Targeting IL-1β in NSCLC: What does the future hold?
Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade.
- Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations
- Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours
- Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved
What is the current state of play of CAR T-cell therapy for B-cell malignancies? Focus on patient selection, safety and new indications
Learn about patient selection for chimeric antigen receptor (CAR) T-cell therapy, adverse event management and the latest developments in CAR T-cell therapies for B-cell malignancies from experts in the field.
- Describe patients who may be eligible for treatment with CAR T-cell therapy
- Review the management of adverse events associated with CAR T-cell therapy
- Discuss how CAR T-cell therapy might impact the treatment pathway for new indications
Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
- Recall the latest clinical trial and real-world data for CAR T-cell therapies in the management of B-cell malignancies
- Describe which patients are eligible for CAR T-cell therapy and discuss the optimal time for referral
- Discuss the safety profile of CAR T-cell therapy and the associated management strategies
- Describe data for new and emerging indications for CAR T-cell therapy
A patient’s journey through the immuno-oncology treatment landscape in melanoma
Watch leading experts explore the impact of immunotherapy incorporating PD-1 blockade on the treatment landscape and patient experience in melanoma.
- Discuss factors to consider when selecting PD-1 inhibitors to treat melanoma
- Understand the rationale for combination regimens incorporating PD-1 blockade
- Analyse the role of long-term clinical and real-world data in informing treatment decisions
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Oncology & Hematology Review (US). 2019;15(2):71–5
Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]
PARP Inhibitors may be Beneficial in a Broader Range of Patients
Oncology & Hematology Review (US). 2019;15(2):66–7
Q. What is the role of PARP-1 in the pathogenesis of cancer? PARP-1 is a protein that resides in the cell nucleus where it plays a role in most, if not all, nuclear functions (e.g. DNA repair, transcription, RNA processing, RNA ribosomal transcription). PARP-1 uses these pathways to assist the cancer cell in its uncontrolled […]
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – the PSV™ Platform
Oncology & Hematology Review (US). 2019:15(2):64–5
Q. What are phosphopeptide tumor targets and why are they good candidates for vaccine and cell therapy development? PTTs are a novel class of neoantigen. They are portions of aberrantly phosphorylated proteins that are presented at the cell surface to the immune system in the context of human leukocyte antigen (HLA) class I molecules. These […]
Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies
European Oncology and Haematology. 2019;15(1):22–8 DOI: https://doi.org/10.17925/EOH.2019.15.1.22
Therapeutic cancer vaccination is a promising strategy that aims to treat late stage disease by using the patient’s own immune system.1 The immune system has the potential to eliminate cancer cells, since cancer cells express antigens that are unique to the tumour or are over-expressed in the tumour. However, despite many years of research, the effective […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!